首页> 美国卫生研究院文献>Molecular Metabolism >Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?
【2h】

Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?

机译:2型糖尿病亚组和潜在的药物策略与胰岛素抵抗和β细胞功能的影响:迈向个性化糖尿病治疗的步骤?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Type 2 diabetes is a syndrome defined by hyperglycaemia that is the result of various degrees of pancreatic β-cell failure and reduced insulin sensitivity. Although diabetes can be caused by multiple metabolic dysfunctions, most patients are defined as having either type 1 or type 2 diabetes. Recently, Ahlqvist and colleagues proposed a new method of classifying patients with adult-onset diabetes, considering the heterogenous metabolic phenotype of the disease. This new classification system could be useful for more personalised treatment based on the underlying metabolic disruption of the disease, although to date no prospective intervention studies have generated data to support such a claim.
机译:2型糖尿病是由高血糖血症定义的综合征,其是各种胰腺β细胞衰竭和降低胰岛素敏感性的结果。虽然糖尿病可能是由多种代谢功能障碍引起的,但大多数患者被定义为具有1型或2型糖尿病。最近,考虑到疾病的异质代谢表型提出了一种分类成人发病糖尿病患者的新方法。这种新的分类系统对于基于疾病的潜在代谢破坏的潜在代谢破坏的更加个性化的治疗有用,尽管迄今为止没有未来的干预研究,则产生数据以支持此类索赔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号